Assessment of the Adherence to a Gluten-free Diet and Nutritional Status of Paediatric Patients With Coeliac Disease

NCT ID: NCT07157137

Last Updated: 2025-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although a gluten-free diet (GFD) is essential for patients with coeliac disease (CD), many do not follow it strictly. Exposure to gluten causes villous atrophy, can deteriorate nutritional status, and can lead to deficiencies. The ESPGHAN recommends combining multiple methods to assess GFD adherence. The Celiac Dietary Adherence Test (CDAT) and measuring the gluten immunogenic peptide in urine (uGIP) or stool (sGIP) were suggested.

This study aims to evaluate and compare the usefulness of an adapted CDAT, the rapid tests for detecting uGIP and sGIP, for assessing adherence to a GFD in children with CD. Additionally, we will assess these children's nutritional status.

Patients, aged 2-18 years, diagnosed with CD, who have been on a GFD for at least 6 months, will be included. Clinical characteristics and anthropometric measurements will be recorded. The adapted CDAT form will be applied. A single urine and stool samples will be collected immediately, and rapid tests for the detection of GIP will be performed. The serum levels of anti-transglutaminase antibodies (IgA), albumin, ferritin, folate, vitamins B12, A, E, 25-OH vitamin D, blood count and lipid profile will be measured.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Celiac Disease in Children Gluten-free Diet

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with coealiac disease.

Patients will undergo anthropometric measurements (body weight, height, and thickness of skin folds over the triceps brachii muscle).

Patient data will be collected during the study, including age, gender, date of coeliac disease diagnosis, duration of gluten-free diet and adherence, history of chronic diseases and congenital defects, medications taken, reported allergies, and family history, with particular emphasis on autoimmune diseases. Guardians/parents of patients under 10 years of age and patients over 10 years of age will be asked to complete a validated Celiac Dietary Adherence Test form. For all patients: IgA tissue transglutaminase antibody levels, aminotransferase activity, complete blood count, and ferritin levels will be measured. An additional 5 ml of venous blood will be collected to measure albumin, folic acid, vitamins B12, A, E, 25-OH vitamin D, and a lipid profile. Additionally, a urine and stool sample will be collected to measure gluten immunogenic peptides.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of coeliac disease according to the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) criteria,
* age from 2 to 18 years of age,
* gluten-free diet use for at least 6 months,
* consent from legal guardians (and the child in case of patients ≥16 years of age) to participate in the study.

Exclusion Criteria

* under 2 years of age and over 18 years of age,
* immunoglobulin A deficiency,
* inflammatory bowel diseases,
* gastrointestinal bleeding or other active bleeding,
* gastric and/or duodenal ulcers,
* liver failure,
* heart failure according to the NYHA II-IV scale,
* acute and chronic renal failure,
* cancer,
* after hematopoietic stem cell transplantation,
* whose legal guardians did not consent to participate in the study,
* who did not consent to participate in the study (applies to patients ≥ 16 years of age).
Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Warsaw

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aleksandra Banaszkiewicz

MD, PhD, Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CD-PL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gluten Reduction and Risk of Celiac Disease
NCT04593888 ACTIVE_NOT_RECRUITING NA